Immunotherapy of Hepatocellular Carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, Hepatocellular Carcinoma, International Publications, Newcastle Disease VirusPersonalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerWT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
/in Dendritic Cells, International Publications, Pancreatic CancerMolecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications, Malignant MelanomaTumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer
/in Dendritic Cells, Gallbladder Cancer, International PublicationsImmunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsOptimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models
/in Dendritic Cells, International Publications, Malignant MelanomaProteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer